The Japanese government has been working to expand the life science industry as well as to establish public R&D management organization in an effort for the country to be able to keep its high technology expertee recognition, and maintain clear global presence in the fast evolving life science field.
  Bio-clusters are being formed especially in Kanto (Tokyo area), also in Hokkaido and Kansai (Osaka area). Moreover, university ventures have started to emerge, such as AnGes MG.
  Large Japanese pharmaceutical industries are beginning to merge such as Daiichi and Sankyo becoming Daiichi-Sankyo, Fujisawa and Yamanouchi becoming Astellas, and other companies are actively starting partnerships with foreign biotech companies. The factors contributing to these changes are the expanding R&D costs and the ever increasing challenge to compete with foreign pharmaceutical companies.
  Although the number of biotech venture companies have increased following the global trend, which ended in 2003, most companies are still in the R&D phase and have not reached to the point to generate revenue. In addition to this situation, the Tokyo Stock Exchange Mother’s board has tightened the restriction for companies to be listed, contributing in slowing down the number of new IPOs.
  Some time may be required for Japanese biotechnology to be industrialized by launching products in the market or partnering with foreign companies. However, other health care services within the life science area is growing, such as food for specified health use (FOSHU).

  PGx is in its early phase in Japan. MediBIC has established total solution for PGx earlier than any other Japanese companies. With the growing awareness of PGx and rising costs as well as utilizing state-of-the-art technologies for R&D, MediBIC consults and provides the efficient way to support the R&D needs for our clients together with our global network.

Domestic/foreign major pharmaceutical companies
University research institutions
Domestic research organizations

SEEMS Inc.
Aroma marketing and consulting business in the area of biotechnology, medical care, environenment and so on.

Corefront
Developing biomaterials for regenerative medicine, applied photo-biotechnology products.

Yasuhiro Hashimoto, M.D.
President and CEO, MediBIC Group
MediBIC Group Headquarter Office
New Nishi-Shinbashi Bldg, 5F,
2-11-6 Nishi-Shinbashi, Minato-ku, Tokyo 105-0003 Japan
TEL +(81)-(0)3-6744-2882
FAX +(81)-(0)3-6744-2662
E-Mail info@medibic.com